Literature DB >> 23997930

Insulin requirements in patients with diabetes and declining kidney function: differences between insulin analogues and human insulin?

Felix Kulozik1, Christoph Hasslacher.   

Abstract

OBJECTIVES: In diabetic nephropathy the decline of renal function causes modifications of the insulin and carbohydrate metabolism resulting in changed insulin requirements. The aim of the present study was to identify potential differences in the requirements of human insulin and various insulin analogues in patients with type 1 diabetes mellitus and renal dysfunction.
METHODS: The insulin requirements of 346 patients with type 1 diabetes mellitus under everyday life circumstances were assessed in an observational study. Simultaneously, laboratory parameters were measured and the estimated glomerular filtration rate (eGFR) was calculated using the formula by Cockcroft-Gault. Medical history and concomitant medication were recorded. The insulin requirements of long- and short-acting insulin were tested for a relationship with the eGFR and laboratory parameters.
RESULTS: The dosage of long-acting human insulin did not show any relation to eGFR. In contrast, a strong positive relation between dosage and renal function was found for insulin glargine and insulin detemir. After classification according to renal function, the insulin dosage at eGFR less than 60 ml/min was 29.7% lower in glargine-treated and 27.3% lower in detemir-treated patients compared with eGFR greater than 90 ml/min. Considering the whole range of eGFR, short-acting human insulin did not show a relation with renal function. Only after classification according to renal function was a dose reduction found for human insulin at eGFR less than 60 ml/min. In contrast, requirements of insulin lispro were significantly related to eGFR over the whole range of eGFR. At eGFR less than 60 ml/min the insulin dosage was 32.6% lower than at eGFR greater than 90 ml/min. The requirements of insulin aspart did not show any association with the eGFR.
CONCLUSIONS: Patients with type 1 diabetes mellitus show different insulin requirements according to the renal function depending on the applied insulin. This finding is essential for the adjustment of insulin therapy in patients with diabetic nephropathy to achieve balanced glycemic control. To determine the underlying mechanisms, further studies on the pharmacokinetics and pharmacodynamics of the different insulins in patients with diabetic nephropathy are needed.

Entities:  

Keywords:  diabetic nephropathy; human insulin; insulin analogues; insulin aspart; insulin detemir; insulin glargin; insulin lispro; insulin requirement; renal insufficiency

Year:  2013        PMID: 23997930      PMCID: PMC3755527          DOI: 10.1177/2042018813501188

Source DB:  PubMed          Journal:  Ther Adv Endocrinol Metab        ISSN: 2042-0188            Impact factor:   3.565


  18 in total

1.  Glucose intolerance in uremic patients: the relative contributions of impaired beta-cell function and insulin resistance.

Authors:  A Alvestrand; M Mujagic; A Wajngot; S Efendic
Journal:  Clin Nephrol       Date:  1989-04       Impact factor: 0.975

2.  Impact of diabetic nephropathy on pharmacodynamic and Pharmacokinetic properties of insulin in type 1 diabetic patients.

Authors:  K Rave; T Heise; A Pfützner; L Heinemann; P T Sawicki
Journal:  Diabetes Care       Date:  2001-05       Impact factor: 19.112

3.  Pharmacokinetics of insulin aspart in obesity, renal impairment, or hepatic impairment.

Authors:  Gregory Holmes; Lawrence Galitz; Peter Hu; William Lyness
Journal:  Br J Clin Pharmacol       Date:  2005-11       Impact factor: 4.335

Review 4.  Clinical pharmacokinetics and pharmacodynamics of insulin aspart.

Authors:  A Lindholm; L V Jacobsen
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

5.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.

Authors:  D M Nathan; S Genuth; J Lachin; P Cleary; O Crofford; M Davis; L Rand; C Siebert
Journal:  N Engl J Med       Date:  1993-09-30       Impact factor: 91.245

6.  [Insulin requirement in patients with type 1 diabetes with reduced renal function: human insulin versus analogue insulin].

Authors:  C Hasslacher; C Vogt; D Raupp; J Dreyhaupt
Journal:  Dtsch Med Wochenschr       Date:  2007-11       Impact factor: 0.628

7.  Decreased insulin requirement in relation to GFR in nephropathic Type 1 and insulin-treated Type 2 diabetic patients.

Authors:  G Biesenbach; A Raml; B Schmekal; G Eichbauer-Sturm
Journal:  Diabet Med       Date:  2003-08       Impact factor: 4.359

8.  Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes.

Authors:  Peter Gaede; Pernille Vedel; Nicolai Larsen; Gunnar V H Jensen; Hans-Henrik Parving; Oluf Pedersen
Journal:  N Engl J Med       Date:  2003-01-30       Impact factor: 91.245

9.  Splanchnic and renal metabolism of insulin in human subjects: a dose-response study.

Authors:  E Ferrannini; J Wahren; O K Faber; P Felig; C Binder; R A DeFronzo
Journal:  Am J Physiol       Date:  1983-06

10.  Plasma exposure to insulin glargine and its metabolites M1 and M2 after subcutaneous injection of therapeutic and supratherapeutic doses of glargine in subjects with type 1 diabetes.

Authors:  Geremia B Bolli; Annke D Hahn; Ronald Schmidt; Tanja Eisenblaetter; Raphael Dahmen; Tim Heise; Reinhard H A Becker
Journal:  Diabetes Care       Date:  2012-10-23       Impact factor: 19.112

View more
  8 in total

Review 1.  Inpatient Glycemic Management in the Setting of Renal Insufficiency/Failure/Dialysis.

Authors:  Ravi Iyengar; Jennifer Franzese; Roma Gianchandani
Journal:  Curr Diab Rep       Date:  2018-08-15       Impact factor: 4.810

2.  Treatment with insulin analogs, especially Glargine and Lispro, associates with better renal function and higher hemoglobin levels in Type 1 diabetic patients with impaired kidney function.

Authors:  Christoph Hasslacher; Felix Kulozik; Justo Lorenzo Bermejo
Journal:  Ther Adv Endocrinol Metab       Date:  2016-05-15       Impact factor: 3.565

3.  The early effect of sunitinib on insulin clearance in patients with metastatic renal cell carcinoma.

Authors:  Anna Maria J Thijs; Cees J Tack; Winette T A van der Graaf; Gerard A Rongen; Carla M L van Herpen
Journal:  Br J Clin Pharmacol       Date:  2016-01-14       Impact factor: 4.335

Review 4.  Glycemic Monitoring and Management in Advanced Chronic Kidney Disease.

Authors:  Rodolfo J Galindo; Roy W Beck; Maria F Scioscia; Guillermo E Umpierrez; Katherine R Tuttle
Journal:  Endocr Rev       Date:  2020-10-01       Impact factor: 19.871

Review 5.  Interactions between kidney disease and diabetes: dangerous liaisons.

Authors:  Roberto Pecoits-Filho; Hugo Abensur; Carolina C R Betônico; Alisson Diego Machado; Erika B Parente; Márcia Queiroz; João Eduardo Nunes Salles; Silvia Titan; Sergio Vencio
Journal:  Diabetol Metab Syndr       Date:  2016-07-28       Impact factor: 3.320

Review 6.  Management of diabetes mellitus in individuals with chronic kidney disease: therapeutic perspectives and glycemic control.

Authors:  Carolina C R Betônico; Silvia M O Titan; Maria Lúcia C Correa-Giannella; Márcia Nery; Márcia Queiroz
Journal:  Clinics (Sao Paulo)       Date:  2016-01       Impact factor: 2.365

7.  The basal to total insulin ratio in outpatients with diabetes on basal-bolus regimen.

Authors:  Elena Castellano; R Attanasio; V A Giagulli; A Boriano; M Terzolo; E Papini; E Guastamacchia; S Monti; A Aglialoro; D Agrimi; E Ansaldi; A C Babini; A Blatto; D Brancato; C Casile; S Cassibba; C Crescenti; M L De Feo; A Del Prete; O Disoteo; F Ermetici; V Fiore; A Fusco; D Gioia; A Grassi; D Gullo; F Lo Pomo; A Miceli; M Nizzoli; M Pellegrino; B Pirali; C Santini; S Settembrini; E Tortato; V Triggiani; A Vacirca; G Borretta
Journal:  J Diabetes Metab Disord       Date:  2018-10-01

Review 8.  Insulin Aspart in the Management of Diabetes Mellitus: 15 Years of Clinical Experience.

Authors:  Kjeld Hermansen; Mette Bohl; Anne Grethe Schioldan
Journal:  Drugs       Date:  2016-01       Impact factor: 9.546

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.